The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
Abstract
Purpose: Anthracycline-induced cardiotoxicity (ACT) is a serious adverse drug reaction limiting anthracycline use and causing substantial morbidity and mortality. Our aim was to identify genetic variants associated with ACT in patients treated for childhood cancer. Patients and Methods: We carried out a study of 2,977 single-nucleotide polymorphisms (SNPs) in 220 key drug biotransformation genes in a discovery cohort of 156 anthracycline-treated children from British Columbia, with replication in a second cohort of 188 children from across Canada and further replication of the top SNP in a third cohort of 96 patients from Amsterdam, the Netherlands. Results: We identified a highly significant association of a synonymous coding variant rs7853758 (L461L) within the SLC28A3 gene with ACT (odds ratio, 0.35; P = 1.8 × 10−5 for all cohorts combined). Additional associations (P < .01) with risk and protective variants in other genes including SLC28A1 and several adenosine triphosphate–binding cassette transporters (ABCB1, ABCB4, and ABCC1) were present. We further explored combining multiple variants into a single-prediction model together with clinical risk factors and classification of patients into three risk groups. In the high-risk group, 75% of patients were accurately predicted to develop ACT, with 36% developing this within the first year alone, whereas in the low-risk group, 96% of patients were accurately predicted not to develop ACT. Conclusion: We have identified multiple genetic variants in SLC28A3 and other genes associated with ACT. Combined with clinical risk factors, genetic risk profiling might be used to identify high-risk patients who can then be provided with safer treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy
Felker, G. M., Thompson, R. E., Hare, J. M., Hruban, R. H., Clemetson, D. E., Howard, D. L., Baughman, K. L., & Kasper, E. K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004133421502 · Cited by 1,723
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Gao, X., Starmer, J., & Martin, E. R. (2008) · Genetic Epidemiology · doi:10.1002/gepi.20310 · Cited by 849
Šimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70018-0 · Cited by 769
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.
Zaman, G. J., Flens, M. J., van Leusden, M. R., de Haas, M., Mülder, H. S., Lankelma, J., Pinedo, H. M., Scheper, R. J., Baas, F., & Broxterman, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.8822 · Cited by 680
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Genetics and Beyond – The Transcriptome of Human Monocytes and Disease Susceptibility
Zeller, T., Wild, P., Szymczak, S., Rotival, M., Schillert, A., Castagne, R., Maouche, S., Germain, M., Lackner, K., Rossmann, H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010693 · Cited by 589
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub4 · Cited by 553
Self-citationWojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeböller, H., Toliat, M. R., Suk, E.-K., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.576850 · Cited by 489
Anthracycline Cardiotoxicity: From Bench to Bedside
Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., & Sawyer, D. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9401 · Cited by 454
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Self-citationRole of Cancer Treatment in Long-Term Overall and Cardiovascular Mortality After Childhood Cancer
Tukenova, M., Guibout, C., Oberlin, O., Doyon, F., Mousannif, A., Haddy, N., Guérin, S., Pacquement, H., Aouba, A., Hawkins, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2267 · Cited by 451
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Anthracycline associated cardiotoxicity in survivors of childhood cancer
Lipshultz, S. E., Alvarez, J. A., & Scully, R. E. (2008) · Heart · doi:10.1136/hrt.2007.136093 · Cited by 379
Kremer, L. C. M., van der Pal, H. J. H., Offringa, M., van Dalen, E. C., & Voûte, P. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf167 · Cited by 354
Self-citationDawson, P. A., Haywood, J., Craddock, A. L., Wilson, M., Tietjen, M., Kluckman, K., Maeda, N., & Parks, J. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306370200 · Cited by 337
van Dalen, E. C., van der Pal, H. J. H., Kok, W. E. M., Caron, H. N., & Kremer, L. C. M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.08.005 · Cited by 284
Self-citationSmith, A. J., van Helvoort, A., van Meer, G., Szabó, K., Welker, E., Szakács, G., Váradi, A., Sarkadi, B., & Borst, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909002199 · Cited by 252
Kremer, L. C. M., van Dalen, E. C., Offringa, M., & Voûte, P. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf118 · Cited by 249
Self-citationCardiac Function in 5-Year Survivors of Childhood Cancer: A Long-term Follow-up Study
van der Pal, H. J., van Dalen, E. C., Hauptmann, M., Kok, W. E., Caron, H. N., van den Bos, C., Oldenburger, F., Koning, C. C., van Leeuwen, F. E., & Kremer, L. C. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.233 · Cited by 191
Self-citationBeyond odds ratios — communicating disease risk based on genetic profiles
Kraft, P. L., Wacholder, S., Cornelis, M. C., Hu, F. B., Hayes, R. B., Thomas, G. D., Hoover, R. N., Hunter, D. J., & Chanock, S. J. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2516 · Cited by 158
van Asperen, J., van Tellingen, O., Tijssen, F., Schinkel, A. H., & Beijnen, J. H. (1998) · British Journal of Cancer · doi:10.1038/sj.bjc.6690019 · Cited by 147
Cardiotoxicity After Childhood Cancer: Beginning With the End in Mind
Lipshultz, S. E., & Adams, M. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5751 · Cited by 147
Rossi, D., Rasi, S., Franceschetti, S., Capello, D., Castelli, A., Paoli, L. D., Ramponi, A., Chiappella, A., Pogliani, E. M., Vitolo, U., et al. (2009) · Leukemia · doi:10.1038/leu.2008.398 · Cited by 122
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub3 · Cited by 113
Self-citationKrishnaswamy, S., Hao, Q., Al-Rohaimi, A., Hesse, L. M., Moltke, L. L., Greenblatt, D. J., & Court, M. H. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081968 · Cited by 108
Okazaki, T., Javle, M. M., Tanaka, M., Abbruzzese, J. L., & Li, D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1555 · Cited by 104
Rajić, V., Aplenc, R., Debeljak, M., Prestor, V. V., Kuželički, N. K., Mlinarič‐Raščan, I., & Jazbec, J. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903177212 · Cited by 97
Andrews, P. A., Brenner, D. E., Chou, F. T., Kubo, H., & Bachur, N. R. (1980) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)00245-4 · Cited by 87
Carleton, B., Poole, R., Smith, M., et al. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1772 · Cited by 84
Self-citationCardiac or cardiopulmonary transplantation in childhood cancer survivors: An increasing need?
Levitt, G., Anazodo, A. C., Burch, M., & Bunch, K. J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.08.006 · Cited by 47
Application of principal component analysis to pharmacogenomic studies in Canada
Visscher, H., Ross, C. J., Dubé, M., Brown, A. M. K., Phillips, M. S., Carleton, B., & Hayden, M. R. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.36 · Cited by 30
Self-citationLate effects in childhood cancer survivors: A review with a framing effect bias?
Fryer, C. J. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22975 · Cited by 14
Cited by
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Self-citationArmenian, S. H., Hudson, M. M., Mulder, R. L., Chen, M. H., Constine, L. S., Dwyer, M., Nathan, P. C., Tissing, W. J. E., Shankar, S., Sieswerda, E., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70409-7 · Cited by 570
Self-citationReview and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity
Lotrionte, M., Biondi-Zoccai, G., Abbate, A., Lanzetta, G., D'Ascenzo, F., Malavasi, V., Peruzzi, M., Frati, G., & Palazzoni, G. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.026 · Cited by 371
Cole, S. P. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.609248 · Cited by 361
Aminkeng, F., Bhavsar, A. P., Visscher, H., Rassekh, S. R., Li, Y., Lee, J. W., Brunham, L. R., Caron, H. N., van Dalen, E. C., Kremer, L. C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3374 · Cited by 278
Self-citation
Metadata
- Authors
- Visscher, H., Ross, C. J. D., Rassekh, S. R., Barhdadi, A., Dubé, M.-P., Al-Saloos, H., Sandor, G. S., Caron, H. N., van Dalen, E. C., Kremer, L. C., van der Pal, H. J., Brown, A. M. K., Rogers, P. C., Phillips, M. S., Rieder, M. J., Carleton, B. C., Hayden, M. R., & Canadian Pharmacogenomics Network for Drug Safety Consortium
- Venue
- Journal of Clinical Oncology
- Published
- 2012-05-01
- Volume
- 30
- Issue
- 13
- Pages
- 1422-1428
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2152922562
- Cited by
- 401
- References
- 36
- FWCI
- 16.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.